Previous close | 56.26 |
Open | 56.45 |
Bid | 0.00 x 900 |
Ask | 57.88 x 1000 |
Day's range | 56.14 - 56.51 |
52-week range | 31.45 - 68.08 |
Volume | |
Avg. volume | 2,807,831 |
Market cap | 10.208B |
Beta (5Y monthly) | 1.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Research head Lange said the drugmaker could launch the pill version of its experimental weight loss drug amycretin this decade. It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy.
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.